215 related articles for article (PubMed ID: 14530903)
1. Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.
McDonald LM; Moran PM; Vythelingum GN; Joseph MH; Stephenson JD; Gray JA
Psychopharmacology (Berl); 2003 Sep; 169(3-4):321-31. PubMed ID: 14530903
[TBL] [Abstract][Full Text] [Related]
2. Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
Zuckerman L; Rimmerman N; Weiner I
Psychopharmacology (Berl); 2003 Sep; 169(3-4):298-307. PubMed ID: 12827344
[TBL] [Abstract][Full Text] [Related]
3. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors.
Backus LI; Sharp T; Grahame-Smith DG
Br J Pharmacol; 1990 Aug; 100(4):793-9. PubMed ID: 2145051
[TBL] [Abstract][Full Text] [Related]
4. Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol.
Hitchcock JM; Lister S; Fischer TR; Wettstein JG
Behav Brain Res; 1997 Oct; 88(1):43-9. PubMed ID: 9401707
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of latent inhibition in the rat at a high dose of clozapine.
Trimble KM; Bell R; King DJ
J Psychopharmacol; 1998; 12(2):215-9. PubMed ID: 9694034
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
7. Latent inhibition is attenuated by noise and partially restored by a 5-HT2A receptor antagonist.
McDonald LM; Moran PM; Vythelingum GN; Joseph MH; Stephenson JD; Gray JA
Behav Pharmacol; 2002 Dec; 13(8):663-7. PubMed ID: 12478218
[TBL] [Abstract][Full Text] [Related]
8. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on progressive ratio schedule performance: evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine.
Zhang Z; Rickard JF; Body S; Asgari K; Bradshaw CM; Szabadi E
Psychopharmacology (Berl); 2005 Sep; 181(2):381-91. PubMed ID: 15830225
[TBL] [Abstract][Full Text] [Related]
10. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
Gogos A; Kwek P; Chavez C; van den Buuse M
J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
[TBL] [Abstract][Full Text] [Related]
11. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
Barak S; Weiner I
Neuropsychopharmacology; 2007 May; 32(5):989-99. PubMed ID: 16971898
[TBL] [Abstract][Full Text] [Related]
12. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Li Z; Ichikawa J; Huang M; Prus AJ; Dai J; Meltzer HY
Psychopharmacology (Berl); 2005 Dec; 183(2):144-53. PubMed ID: 16220333
[TBL] [Abstract][Full Text] [Related]
13. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
14. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo.
Yadav PN; Kroeze WK; Farrell MS; Roth BL
J Pharmacol Exp Ther; 2011 Oct; 339(1):99-105. PubMed ID: 21737536
[TBL] [Abstract][Full Text] [Related]
15. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
Abekawa T; Honda M; Ito K; Koyama T
Psychopharmacology (Berl); 2003 Sep; 169(3-4):247-56. PubMed ID: 12898123
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Gaisler-Salomon I; Weiner I
Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice.
Chang T; Meyer U; Feldon J; Yee BK
Psychopharmacology (Berl); 2007 Apr; 191(2):211-21. PubMed ID: 17180617
[TBL] [Abstract][Full Text] [Related]
18. The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro.
Olijslagers JE; Perlstein B; Werkman TR; McCreary AC; Siarey R; Kruse CG; Wadman WJ
Eur J Pharmacol; 2005 Sep; 520(1-3):77-85. PubMed ID: 16154561
[TBL] [Abstract][Full Text] [Related]
19. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.
Weiner I; Shadach E; Tarrasch R; Kidron R; Feldon J
Biol Psychiatry; 1996 Nov; 40(9):834-43. PubMed ID: 8896769
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat.
Misane I; Johansson C; Ogren SO
Br J Pharmacol; 1998 Oct; 125(3):499-509. PubMed ID: 9806333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
